Your session is about to expire
← Back to Search
INCB057643 +/- Ruxolitinib for Myelofibrosis (LIMBER Trial)
LIMBER Trial Summary
This trial is testing a new drug, INCB057643, to see if it is safe and effective at treating myelofibrosis and other myeloid neoplasms either alone or in combination with another drug, ruxolitinib.
LIMBER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLIMBER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LIMBER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing to have a bone marrow test before treatment starts.I have previously taken a BET inhibitor and stopped due to side effects.My condition is confirmed as primary or secondary myelofibrosis according to WHO 2016.I am part of the dose escalation and expansion phase for myelofibrosis treatment.My condition is a type of myelofibrosis, confirmed by tests and considered high-risk.I had a stem cell transplant from a donor within the last 6 months.I am not on any other cancer treatments.I have been on a stable dose of ruxolitinib alone for at least 8 weeks.You agree not to get pregnant or father children during the study.I am currently taking ruxolitinib and can continue without stopping.I am 18 years old or older.I am willing to have a bone marrow test before treatment starts.I have an active hepatitis B or C infection, or I'm at risk for hepatitis B reactivation.I've had treatment before, it didn't work or I couldn't tolerate it, and there's no other known beneficial treatment.I am not eligible for treatments that could potentially cure my condition, like stem-cell transplantation.My MDS is classified from very low to high risk according to IPSS-R.My spleen is enlarged and can be felt at least 5 cm below my ribcage.I do not have juvenile myelomonocytic leukemia.My condition is a relapse or resistant to treatment for myelofibrosis, MDS, or MDS/MPN.I have received treatment before.My condition is a type of blood cancer classified as MDS/MPN according to WHO 2016.My condition is a type of blood cancer that has returned or didn't respond to treatment.My condition is a specific type of disease.My spleen is enlarged and can be felt more than 10 cm below my rib cage.I have myelofibrosis and have been treated with a JAK inhibitor.My condition is...I am not eligible for treatments that could potentially cure my condition, like stem-cell transplantation.
- Group 1: Part 2 : INCB057643 Combination with Ruxolitinib
- Group 2: Part 1 : INCB057643 Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research still recruiting participants?
"Indeed, the clinicaltrials.gov webpage indicates that this trial is still in progress and recruiting patients. It was initiated on February 23rd 2021 and its most recent changes were made on October 17th 2022; the study requires 39 participants to be recruited from 12 different medical centres."
What potential side effects should patients be aware of when taking INCB057643?
"Due to limited information regarding INCB057643's safety and efficacy, our team at Power assigns it a score of 1 on the scale from 1-3."
In how many areas is this investigation being conducted?
"To date, 12 clinical trial sites are enrolling patients for this medical study. These include the University of Colorado Cancer Center in Aurora, University of North carolina At Chapel Hill in Chapel Hill and Seattle Cancer Care Alliance in Seattle plus other locations."
What is the current survey size for this experiment?
"Affirmative. According to clinicaltrials.gov, this research endeavour has been actively recruiting since its initial posting on February 23rd 2021 and is currently searching for 39 participants from 12 sites."
Are there any recorded precedents of investigations involving INCB057643?
"The National Institutes of Health Clinical Center's 9000 Rockville Pike location was where INCB057643 received its first scientific investigation in 2002. Presently, 97 trials are actively recruiting participants with Aurora, North carolina housing a large portion of them; 93 studies have been completed to date."
What medical conditions can be managed through the use of INCB057643?
"INCB057643 is most commonly prescribed to patients with polycythemia vera. Additionally, this medication can be effective for treating other diseases such as refractory/intolerant hydroxyurea-associated polycythaemia and primary myelofibrosis."
Share this study with friends
Copy Link
Messenger